AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38830992 — intervention group
Group type: EXPERIMENTAL
Intervention: satri-cel monotherapy in 61 patients with standard chemotherapy-refractory gastrointestinal cancers
Number of subjects: 98
Study 38830992 — intervention group
Group type: EXPERIMENTAL
Intervention: satri-cel plus anti-PD-1 therapy in 15 patients with standard chemotherapy-refractory gastrointestinal cancers
Number of subjects: 98
Study 38830992 — intervention group
Group type: EXPERIMENTAL
Intervention: satri-cel as sequential treatment after first-line therapy in five patients with gastrointestinal cancers
Number of subjects: 98
Study 38830992 — intervention group
Group type: EXPERIMENTAL
Intervention: satri-cel monotherapy in two patients with anti-CLDN18.2 monoclonal antibody-refractory gastric cancer
Number of subjects: 98
Study 38830994 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab, lenalidomide, and dexamethasone (IsaRd)
Number of subjects: 270
Study 38830994 — intervention group
Group type: COMPARATOR
Intervention: Isatuximab, lenalidomide, dexamethasone, and bortezomib (Isa-VRd)
Number of subjects: 270
Study 38831029 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam-flumazenil
Number of subjects: 53
Study 38831029 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 53
Study 38831218 — intervention group
Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 80
Study 38831218 — intervention group
Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 80
Study 38831218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 80
Study 38831266 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group intervention implemented by trained community volunteers
Number of subjects: 771
Study 38831266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 771
Study 38831365 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 15
Study 38831365 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and education for clinics
Number of subjects: 15
Study 38831365 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 15
Study 38831409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer training course
Number of subjects: 408
Study 38831415 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated MOUD and HIV treatment/prevention through a mobile unit
Number of subjects: 5
Study 38831415 — intervention group
Group type: COMPARATOR
Intervention: Epidemiological data
Number of subjects: 5
Study 38832001 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs® 7630
Number of subjects: 208
Study 38832001 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 208
Study 38832105 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous daratumumab
Number of subjects: 21
Study 38832435 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index
Number of subjects: 40
Study 38832435 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 40
Study 38832504 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg thrice daily
Number of subjects: 65
Study 38832504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 38832504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 65
Study 38832791 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression and/or stabilization
Number of subjects: 280
Study 38832837 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium screening
Number of subjects: 1064
Study 38832837 — intervention group
Group type: EXPERIMENTAL
Intervention: PICU stay longer than 15 days
Number of subjects: 1064
Study 38832837 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 1064
Study 38832837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusions
Number of subjects: 1064
Study 38832837 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusions
Number of subjects: 1064
Study 38832837 — intervention group
Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 1064
Study 38832837 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusions of opioids
Number of subjects: 1064
Study 38832837 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusions of ketamine
Number of subjects: 1064
Study 38832949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC (10 mg)
Number of subjects: 56
Study 38832949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 38832972 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus VRd
Number of subjects: 446
Study 38832972 — intervention group
Group type: COMPARATOR
Intervention: VRd
Number of subjects: 446
Study 38832995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary pressure measurements
Number of subjects: 0
Study 38832995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of adenosine
Number of subjects: 0
Study 38832995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of adenosine
Number of subjects: 0
Study 38833007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent-scanned continuous glucose monitoring (isCGM) system in group A
Number of subjects: 400
Study 38833007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent-scanned continuous glucose monitoring (isCGM) system in group B
Number of subjects: 400
Study 38833007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent-scanned continuous glucose monitoring (isCGM) system in both groups
Number of subjects: 400
Study 38833140 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapokibart (75-600 mg, subcutaneous)
Number of subjects: 72
Study 38833140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 38833144 — intervention group
Group type: EXPERIMENTAL
Intervention: IVL3001 (12-36 mg)
Number of subjects: 40
Study 38833144 — intervention group
Group type: EXPERIMENTAL
Intervention: IVL3001 (12-36 mg) every 4 weeks
Number of subjects: 40
Study 38833144 — intervention group
Group type: EXPERIMENTAL
Intervention: IVL3001
Number of subjects: 40
Study 38833250 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric service dog for PTSD (n = 81)
Number of subjects: 156
Study 38833250 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 75)
Number of subjects: 156
Study 38833312 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR+ extracellular vesicles (CAR+EVs)
Number of subjects: 100
Study 38833311 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib treatment
Number of subjects: 0
Study 38833348 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 473
Study 38833348 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 473
Study 38833360 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive ITPLT model for post-LT tolerance
Number of subjects: 2228
Study 38833360 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical factors associated with tolerance achievement
Number of subjects: 2228
Study 38833360 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful tapering of immunosuppressants (IS)
Number of subjects: 2228
Study 38833442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled xenon during targeted temperature management (TTM) at 33°C for 24 hours
Number of subjects: 110
Study 38833442 — intervention group
Group type: COMPARATOR
Intervention: Control group (TTM at 33°C without xenon)
Number of subjects: 110
Study 38833560 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine dosing intervals less than 3 minutes
Number of subjects: 382
Study 38833575 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental technique (inserting the orogastric tube through a modified nipple of a bottle)
Number of subjects: 71
Study 38833575 — intervention group
Group type: COMPARATOR
Intervention: Usual technique (inserting the tube directly into the newborn's mouth without support)
Number of subjects: 71
Study 38833575 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental technique
Number of subjects: 71
Study 38833575 — intervention group
Group type: COMPARATOR
Intervention: Usual technique
Number of subjects: 71
Study 38833590 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily for 10 days
Number of subjects: 123
Study 38833590 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 123
Study 38833643 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + Endocrine Therapy (ET) (10 mg orally once daily for 1 year)
Number of subjects: 1939
Study 38833643 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Endocrine Therapy (ET)
Number of subjects: 1939
Study 38833643 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + ET in postmenopausal patients (N = 1,221)
Number of subjects: 1939
Study 38833643 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + ET in premenopausal patients (N = 571)
Number of subjects: 1939
Study 38833658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks
Number of subjects: 480
Study 38833658 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) - investigator's choice of regorafenib or trifluridine/tipiracil
Number of subjects: 480
Study 38833971 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenously every 2 weeks)
Number of subjects: 1154
Study 38833975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cawthorne-Cooksey exercises
Number of subjects: 50
Study 38833975 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical hippotherapy exercises
Number of subjects: 50
Study 38833975 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cawthorne-Cooksey)
Number of subjects: 50
Study 38833992 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 733
Study 38833992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 38834087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitazalimab 900 μg/kg with mFOLFIRINOX
Number of subjects: 70
Study 38834087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitazalimab 450 μg/kg with mFOLFIRINOX
Number of subjects: 70
Study 38834087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitazalimab with mFOLFIRINOX
Number of subjects: 70
Study 38834220 — intervention group
Group type: EXPERIMENTAL
Intervention: Clascoterone cream 1% applied twice daily for 14 days
Number of subjects: 69
Study 38834226 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB)
Number of subjects: 0
Study 38834226 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 0
Study 38834226 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB
Number of subjects: 0
Study 38834319 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells)
Number of subjects: 18
Study 38834319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and postnatal administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells)
Number of subjects: 18
Study 38834319 — intervention group
Group type: COMPARATOR
Intervention: Historical and untreated prospective controls
Number of subjects: 18
Study 38834351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 0
Study 38834351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38834399 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor maintenance therapy
Number of subjects: 113
Study 38834399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 38834399 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor maintenance therapy (TP53wt/pMMR EC)
Number of subjects: 113
Study 38834399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TP53wt/pMMR EC)
Number of subjects: 113
Study 38834399 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor maintenance therapy (TP53wt/dMMR EC)
Number of subjects: 113
Study 38834399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TP53wt/dMMR EC)
Number of subjects: 113
Study 38834393 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenogroup 2 (PG2) - younger smokers with ST-segment elevation myocardial infarction
Number of subjects: 1499
Study 38834393 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenogroup 3 (PG3) - elderly patients with heart failure with preserved ejection fraction and conduction disturbances
Number of subjects: 1499
Study 38834393 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenogroup 4 (PG4) - patients with acute heart failure with reduced ejection fraction
Number of subjects: 1499
Study 38834393 — intervention group
Group type: COMPARATOR
Intervention: Phenogroup 1 (PG1) - typically patients with non-ST-segment elevation myocardial infarction
Number of subjects: 1499
Study 38834432 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN023 (0.3 mg/kg)
Number of subjects: 448
Study 38834432 — intervention group
Group type: COMPARATOR
Intervention: HRIG (0.133 mL/kg)
Number of subjects: 448
Study 38834540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 61
Study 38834540 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 61
Study 38834634 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (multispecies-multistrain)
Number of subjects: 14
Study 38834634 — intervention group
Group type: COMPARATOR
Intervention: Prebiotic (oat bran)
Number of subjects: 14
Study 38834744 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) followed by nivolumab (240 mg) and surgery
Number of subjects: 44
Study 38834776 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized bacteriophage therapy (BT)
Number of subjects: 100
Study 38834776 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized bacteriophage therapy (BT) with concomitant antibiotics
Number of subjects: 100
Study 38834847 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Cog paradigm
Number of subjects: 1201
Study 38834847 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1201
Study 38834996 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 94
Study 38834996 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 94
Study 38835035 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive gender-transformative intervention of sexual education (ENFOCATE -Focus-on-)
Number of subjects: 609
Study 38835046 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month physical rehabilitation intervention program
Number of subjects: 60
Study 38835046 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 38835058 — intervention group
Group type: EXPERIMENTAL
Intervention: Community dialogue approach (FH=FW)
Number of subjects: 70
Study 38835061 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation (< 6 hours)
Number of subjects: 178
Study 38835061 — intervention group
Group type: COMPARATOR
Intervention: Delayed extubation (6-12 hours)
Number of subjects: 178
Study 38835083 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-flow restricted resistance training (BFR-T) during a combined pre- and postoperative period for a total of 6-10 weeks.
Number of subjects: 0
Study 38835083 — intervention group
Group type: COMPARATOR
Intervention: Control group (exact details not specified).
Number of subjects: 0
Study 38835083 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-flow restricted resistance training (BFR-T) with protein supplementation.
Number of subjects: 0
Study 38835083 — intervention group
Group type: COMPARATOR
Intervention: Control group (exact details not specified) with protein supplementation.
Number of subjects: 0
Study 38835091 — intervention group
Group type: EXPERIMENTAL
Intervention: True-AI arm (AI-assisted interpretation of head CTA)
Number of subjects: 6450
Study 38835091 — intervention group
Group type: COMPARATOR
Intervention: Sham-AI arm (Sham AI-assisted interpretation of head CTA)
Number of subjects: 6450
Study 38835091 — intervention group
Group type: EXPERIMENTAL
Intervention: True-AI arm
Number of subjects: 6450
Study 38835091 — intervention group
Group type: EXPERIMENTAL
Intervention: True-AI arm and Sham-AI arm
Number of subjects: 6450
Study 38835104 — intervention group
Group type: EXPERIMENTAL
Intervention: Married marital status
Number of subjects: 629
Study 38835104 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical health-related quality of life (HRQoL)
Number of subjects: 629
Study 38835104 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater levels of social support
Number of subjects: 629
Study 38835146 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally delivered treatment comprising exercise and patient education
Number of subjects: 682
Study 38835146 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 682
Study 38835235 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg (induction)
Number of subjects: 1021
Study 38835235 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg, 15 mg (maintenance)
Number of subjects: 1021
Study 38835333 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance-controlled RF ablation of the PNN
Number of subjects: 36
Study 38835400 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium binders for treating hyperkalemia
Number of subjects: 0
Study 38835548 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + EMDR
Number of subjects: 79
Study 38835548 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 79
Study 38836335 — intervention group
Group type: EXPERIMENTAL
Intervention: @ctivehip tele-rehabilitation
Number of subjects: 71
Study 38836335 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study 38836358 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Number of subjects: 0
Study 38836358 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin treatment
Number of subjects: 0
Study 38836358 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental model of AS in mice
Number of subjects: 0
Study 38836358 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38836419 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0
Study 38836419 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38836471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine measurement in sputum samples during exacerbation
Number of subjects: 99
Study 38836606 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VNS paired with rehabilitation
Number of subjects: 106
Study 38836606 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation paired with rehabilitation (Controls)
Number of subjects: 106
Study 38836759 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC102 + Temozolomide (TMZ)
Number of subjects: 19
Study 38836997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-dkst
Number of subjects: 59
Study 38837034 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based composite (RBC) (Spectrum TPH3, Dentsply Sirona)
Number of subjects: 33
Study 38837034 — intervention group
Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RMGIC) (Riva Light Cure, SDI)
Number of subjects: 33
Study 38837034 — intervention group
Group type: COMPARATOR
Intervention: RMGIC
Number of subjects: 33
Study 38837034 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RBC and RMGIC
Number of subjects: 33
Study 38837133 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-oriented, material-based cognitive behavioral therapy (SEKT)
Number of subjects: 305
Study 38837133 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive, patient-centered, emotion-focused therapy (FEST)
Number of subjects: 305
Study 38837133 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder type 2 (BD 2)
Number of subjects: 305
Study 38837144 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib, 200 mg, by mouth once daily for 12 weeks
Number of subjects: 20
Study 38837194 — intervention group
Group type: EXPERIMENTAL
Intervention: VR dual-task training program
Number of subjects: 188
Study 38837194 — intervention group
Group type: COMPARATOR
Intervention: VR headset app showing nature videos (Control)
Number of subjects: 188
Study 38837194 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention and working memory (Central Nervous System Vital Signs computerized cognitive battery)
Number of subjects: 188
Study 38837194 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (World Health Organization-5 Well-Being Index)
Number of subjects: 188
Study 38837194 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (EQ-5D-5L)
Number of subjects: 188
Study 38837194 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety (General Anxiety Disorder 7-item questionnaire)
Number of subjects: 188
Study 38837208 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 412
Study 38837208 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 412
Study 38837208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary fixation
Number of subjects: 412
Study 38837237 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin cream
Number of subjects: 1166
Study 38837237 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 1166
Study 38837237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1166
Study 38837237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 1166
Study 38837237 — intervention group
Group type: COMPARATOR
Intervention: Enalapril ointment
Number of subjects: 1166
Study 38837237 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy
Number of subjects: 1166
Study 38837237 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 1166